GC can up-regulate the expression of FGF23 in bone and plasma, activating FGFR3 receptors and contributing to GC-induced growth disorders via the FGF23/Klotho/FGFR3 pathway (48). This evidence concerns the gene FGF23 and hereditary endocrine growth disease.